TransMedics Group (HAM:8T8) PE Ratio without NRI: 15.98 (As of Jun. 30, 2026) — 75% Below Median


HAM:8T8 TransMedics Group Inc HAM:8T8
69 GF Score
Price €60.02
GF Value €162.08
! 9 Warning Signs
View Full Analysis

What is TransMedics Group PE Ratio without NRI?

TransMedics Group HAM:8T8 -9.99% 69 PE Ratio without NRI is 15.98 as of Jun. 30, 2026, which is 75% below its 10-year median of 63.37. GuruFocus rates HAM:8T8 with a GF Score™ of 69/100 and a GF Value™ of €162.08. The stock has 9 warning signs investors should review. Among 446 Medical Devices & Instruments companies, TransMedics Group ranks better than 73.09% on this metric.

The PE Ratio without NRI, or P/E Ratio without non-recurring items, is a financial ratio used to compare a company's market price to its EPS without NRI. As of today (2026-06-30), TransMedics Group's share price is €60.02. TransMedics Group's EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 was €3.76. Therefore, TransMedics Group's PE Ratio without NRI for today is 15.98.

During the past 10 years, TransMedics Group's highest PE Ratio without NRI was 4182.38. The lowest was 14.42. And the median was 63.37.

TransMedics Group's EPS without NRI for the three months ended in Mar. 2026 was €0.17. Its EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 was €3.76.

As of today (2026-06-30), TransMedics Group's share price is €60.02. TransMedics Group's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was €3.77. Therefore, TransMedics Group's PE Ratio (TTM) for today is 15.92.

Good Sign:

TransMedics Group Inc stock PE Ratio (=15.55) is close to 2-year low of 14.36.

During the past years, TransMedics Group's highest PE Ratio (TTM) was 4391.50. The lowest was 14.36. And the median was 62.28.

TransMedics Group's EPS (Diluted) for the three months ended in Mar. 2026 was €0.17. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was €3.77.

TransMedics Group's EPS (Basic) for the three months ended in Mar. 2026 was €0.18. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 was €4.31.


TransMedics Group  (HAM:8T8) PE Ratio without NRI Explanation

The PE Ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.

In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio is positive. Also for stocks with the same PE Ratio, the one with faster growth business is more attractive.

If a company loses money, the PE Ratio becomes meaningless.

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio divided by the growth ratio. He thinks a company with a PE Ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio of 20, instead of a company growing 10% a year with a PE Ratio of 10.

Because the PE Ratio measures how long it takes to earn back the price you pay, the PE Ratio can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.

Similar to the PE Ratio or PS Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PE Ratio without NRI measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

Investors need to be aware that the PE Ratio can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratio s are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio.


TransMedics Group PE Ratio without NRI Related Terms


TransMedics Group PE Ratio without NRI Historical Data

* Premium members only.

The historical data trend for TransMedics Group's PE Ratio without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

TransMedics Group PE Ratio without NRI Chart

TransMedics Group Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
PE Ratio without NRI
Get a 7-Day Free Trial Premium Member Only Premium Member Only N/A N/A N/A 61.73 24.98

TransMedics Group Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
PE Ratio without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 50.32 70.64 45.72 24.98 22.68

HAM:8T8 vs AXGN, BFLY, ESTA: PE Ratio without NRI Comparison

For the Medical Devices subindustry, TransMedics Group's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


TransMedics Group PE Ratio without NRI vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, TransMedics Group's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where TransMedics Group's PE Ratio without NRI falls into.


HAM:8T8
69GF Score
TransMedics Group Inc HAM:8T8
PE Ratio without NRI is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

TransMedics Group PE Ratio without NRI Calculation

The PE Ratio without NRI, or P/E Ratio without non-recurring items, is a financial ratio used to compare a company's market price to its EPS without NRI. Regular PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than regular PE Ratio.

TransMedics Group's PE Ratio without NRI for today is calculated as

PE Ratio without NRI=Share Price/ EPS without NRI
=60.02/3.756
=15.98

TransMedics Group's Share Price of today is €60.02.
TransMedics Group's EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €3.76.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

There are at least three kinds of PE Ratios used by different investors. They are Trailing Twelve Month PE Ratio, Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio based on inflation-adjusted normalized PE Ratio is called Shiller PE Ratio, after Yale professor Robert Shiller.

In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.

In the calculation of PE Ratio (TTM), the earnings per share used are the earnings per share over the past 12 months.

For Forward PE Ratio, the earnings are the expected earnings for the next twelve months.

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.

Frequently Asked Questions Learn more about PE Ratio without NRI →
What does a PE Ratio without NRI of 15.98 mean?
TransMedics Group (HAM:8T8) has a PE Ratio without NRI of 15.98 as of Jun. 30, 2026. P/E without nonrecurring items is the ratio of share price to a company's earnings less one-time charges. View historical data on TransMedics Group and its competitors. This is 75% below median its historical median of 63.37. Over the past decade, TransMedics Group's PE Ratio without NRI has ranged from 14.42 to 4,182.38. According to the industry distribution chart, TransMedics Group ranks #120 out of 446 companies in the Medical Devices & Instruments industry, placing it in the top 26.9%.
Is TransMedics Group's PE Ratio without NRI too high?
TransMedics Group's current PE Ratio without NRI of 15.98 is 75% below median its 10-year median of 63.37. Over the past 10 years, this metric has ranged from a low of 14.42 to a high of 4,182.38. The Medical Devices & Instruments industry median PE Ratio without NRI is 23.51. TransMedics Group's value of 15.98 is 32% below this industry median. Based on the distribution chart, TransMedics Group ranks #120 out of 446 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, TransMedics Group has a GF Score™ of 69/100, reflecting its overall financial health beyond just this single metric.
How does TransMedics Group's PE Ratio without NRI compare to AXGN and BFLY?
According to the Medical Devices & Instruments industry distribution chart, TransMedics Group ranks #120 out of 446 companies for PE Ratio without NRI. This puts TransMedics Group in the upper half of its industry. The industry median PE Ratio without NRI is 23.51. TransMedics Group's value of 15.98 is 32% below this benchmark. Historically, TransMedics Group's own PE Ratio without NRI has ranged from 14.42 to 4,182.38 over the past decade. While the company's 10-year median is 63.37 vs. the industry median of 23.51, TransMedics Group has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PE Ratio without NRI for a Medical Devices & Instruments company?
The median PE Ratio without NRI among Medical Devices & Instruments companies is 23.51, based on 446 companies in the industry. Companies in the top quartile (top 25%) have a PE Ratio without NRI significantly above this median, while those in the bottom quartile fall well below. However, PE Ratio without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. TransMedics Group's current PE Ratio without NRI of 15.98 is 32% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PE Ratio without NRI mean?
A high PE Ratio without NRI can signal that a stock is expensive relative to its fundamentals. P/E without nonrecurring items is the ratio of share price to a company's earnings less one-time charges. View historical data on TransMedics Group and its competitors. For the Medical Devices & Instruments industry, the median PE Ratio without NRI is 23.51 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. TransMedics Group's current PE Ratio without NRI is 15.98, which is 75% below median its own 10-year median of 63.37. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TransMedics Group stock overvalued right now?
TransMedics Group (HAM:8T8) has a current PE Ratio without NRI of 15.98. The stock's GF Value™ is €162.08, compared to a current price of €60.02 — trading 63% below its estimated fair value. The current PE Ratio without NRI is 15.98, which is 75% below median its 10-year median of 63.37 and 32% below the Medical Devices & Instruments industry median of 23.51. TransMedics Group's overall GF Score™ is 69/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PE Ratio without NRI calculated?
PE Ratio without NRI is calculated from a company's financial statements. For TransMedics Group (HAM:8T8), the current PE Ratio without NRI is 15.98 as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is TransMedics Group (HAM:8T8) Overvalued in 2026?

Based on GuruFocus' analysis, TransMedics Group stock appears to be undervalued. The current stock price of €60.02 is trading 63% below its estimated GF Value™ of €162.08.

Key valuation signals for HAM:8T8:

  • PE Ratio without NRI: 15.98 (75% below median its 10-year median of 63.37)
  • GF Value™: €162.08 vs. price of €60.02 (63% below fair value)
  • GF Score™: 69/100 with 9 warning signs
  • Industry Position: 32% below the Medical Devices & Instruments median (#120 of 446)

No single metric tells the full story. See the HAM:8T8 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


TransMedics Group Business Description

Address 200 Minuteman Road, Andover, MA, USA, 01810
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System (OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization, and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.
69GF Score

Get the complete analysis for HAM:8T8

PE Ratio without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€60.02
Price
€162.08
GF Value